Enrique Grande, Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared on X:
“3–5% of all renal cell carcinomas are hereditary – yet most patients are never tested.
While germline testing is standard in breast, ovarian and colorectal cancer, a significant gap remains in urological malignancies despite the actionability of hereditary RCC syndromes.
Time to close that gap.”
Title: Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine
Authors: Fanni Santaa, Liang Cheng
Other articles about RCC on OncoDaily.